Novartis already bought into optogenetic gene therapy technology last year, but the Swiss Pharma wants more. Enter Arctos Medical, which will now join Novartis with its gene therapy program for vision ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced retinitis pigmentosa who received intravitreal optogenetics gene therapy in a phase 1/2a ...

This groundbreaking neurotechnology allows scientists to activate neurons with light, opening new frontiers in brain research ...

Scientists for the very first time say they have partially restored the vision of a man who has been blind for 40 years — and they did it using algae proteins. It marks a major milestone in the ...

Scientists for the very first time say they have partially restored the vision of a man who has been blind for 40 years — and they did it using algae proteins. It marks a major milestone in the ...

Please provide your email address to receive an email when new articles are posted on . New technology like optogenetics, which uses the application of light to genetically modify target cells, offers ...

Effective treatments for incontinence are urgently needed. Now, a multi-institutional team of researchers has developed a wireless system that can measure bladder function in freely moving rats over ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...

A new paper in Oxford Open Neuroscience, published by Oxford University Press, indicates that optogenetics, suggested as a promising treatment for many psychological and neurological conditions, may ...

NEW YORK CITY -- A form of light therapy led to durable improvement in visual acuity for patients with dry age-related macular degeneration, according to interim results from an ongoing randomized ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris: SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative ...